Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Injecting platelet-rich plasma or applying it with a laser or microneedling can treat hair loss effectively. The laser and microneedling methods cause less pain.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

AB+ blood group is more common in alopecia areata patients.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Immunotherapy can help treat severe alopecia areata.

JAK inhibitors show promise as a future treatment for hair loss.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

These specific gene polymorphisms are not linked to Alopecia Areata in Egyptians.

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Certain scalp tissue features can predict how well alopecia areata responds to steroid injections.

Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Trichoscopy helps diagnose and monitor alopecia areata by looking at a combination of specific hair and scalp features.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Stem cell therapy may help treat tough hair loss cases.

Platelet-rich plasma (PRP) is a safe and potentially effective way to treat hair loss, especially when combined with minoxidil.

Most hair loss disorders can be accurately diagnosed and treated in an outpatient setting.

Minoxidil effectively and safely treats patchy hair loss, but more research needed.

Non-immune factors play a significant role in alopecia areata.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.